13F Pro

SEC Form 4 reporting owner

Sullivan Timothy Eugene

Sullivan Timothy Eugene has filed 4 Form 4 transactions reported between January 13, 2026 and January 28, 2026, as Chief Financial Officer of Apellis Pharmaceuticals, Inc..

Name as filed: Sullivan Timothy Eugene

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$367K
3 lines
Companies
1
with Form 4 filings
Latest transaction
Jan 28, 2026
transaction date

Roles and reported holdings

  • APLSApellis Pharmaceuticals, Inc.
    Jan 13, 2026 – Jan 28, 2026

    Chief Financial Officer

    Held directly93,901 sh as of Jan 22, 2026 · Form 4

    24 months: $367K sold

Transaction history

All 4 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jan 28, 2026APLSChief Financial OfficerGrant or awardCode A · direct58,140—Form 4
Jan 22, 2026APLSChief Financial OfficerOpen-market saleCode S · direct10,287$224K@ $21.77Form 4
Jan 20, 2026APLSChief Financial OfficerOpen-market saleCode S · direct2,892$57K@ $19.79Form 4
Jan 13, 2026APLSChief Financial OfficerOpen-market saleCode S · direct3,856$86K@ $22.19Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.